Print Page     Close Window     

SEC Filings

ADVANCED ACCELERATOR APPLICATIONS S.A. filed this Form SC14D9C on 11/17/2017
Entire Document




About Molecular Nuclear Medicine (“MNM”)


Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions, and to treat various diseases, like cancer. The technique works by injecting targeted radiopharmaceuticals into the patient’s body that accumulate in the organs or lesions and reveal specific biochemical processes. MNM can be divided in two branches: Molecular Nuclear Diagnostics and Molecular Nuclear Therapy. Molecular nuclear diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages. Molecular nuclear therapy uses radioactive sources (radionuclides) to treat a range of tumor types. Using short-range particles, this therapy can target tumors with little effect on normal tissues.


Reconciliation of adjusted EBITDA to net loss for the period from continuing operations for the three and nine months ended September 30, 2017 and 2016


   Nine months  Three months  Nine months
   September 30, 2017  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016
   in USD thousands(1)  In € thousands  In € thousands
Net loss for the period from continuing operations   (51,898)   (22,741)   (6,243)   (43,933)   (10,651)
Finance income
(including changes in fair value of contingent consideration)
   (10,098)   (1,214)   (427)   (8,548)   (812)
Finance costs
(including changes in fair value of contingent consideration)
   40,930    19,577    1,502    34,648    4,659 
Income taxes   1,977    689    25    1,674    (422)
Depreciation and amortization   13,273    3,817    3,411    11,236    9,838 
Adjusted EBITDA   (5,816)   128    (1,732)   (4,923)   2,612 
Sales   125,702    37,245    26,723    106,410    81,282 
Adjusted EBITDA margin   -4.63%   0.34%   -6.48%   -4.63%   3.21%


(1) Translated solely for convenience into dollars at the noon buying rate of  EUR 1.00 = USD 1.1813 at September 29, 2017.


Additional Information


This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. The tender offer for the outstanding ordinary shares and American Depositary Shares of AAA described in this press release has not commenced. At the time the tender offer is commenced, Novartis and an indirect wholly owned subsidiary of Novartis (“Purchaser”) will file, or will cause to be filed, a Schedule TO Tender Offer Statement with the U.S. Securities and Exchange Commission (the “SEC”) and AAA will file a Schedule 14D-9 Solicitation/Recommendation Statement with the SEC, in each case with respect to the tender offer. The Schedule TO Tender Offer Statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the Schedule 14D-9 Solicitation/Recommendation Statement will contain important information that should be read



© -20 Advanced Accelerator Applications - All rights reserved .